Access immediate expertise

The training and expertise required for each CMS update—like the Sepsis Bundle (Sep-1) or the Physician Quality Reporting System (PQRS)—can derail your department for weeks. Instead of losing time trying to learn all the changes, make a quick phone call to Q‑Centrix.

How it works:

01

Data is abstracted or extracted from the EHR.

02

The information is populated within Q-Apps or a vendor tool.

03

Our team of quality information specialists analyze the data for accuracy.

04

The data is sent to our partner hospitals for approval and submission.

05

Our partner hospital reviews the Fallout Report within our Core Technology.

Creating a cost-benefit analysis?

Read about Sharp Healthcare's experience.

Q-Centrix Savings Calculator

* required field
Calculator
Please enter the Number of FTEs
Please enter the Average Pay Per Hour
Please enter the Average # of hours per week the FTE spends on abstraction

Assumptions

Please enter the Benefits %
Please enter the Overhead

Reduce Abstraction Costs

Your Total Cost

$ / year

Your Savings Range

$ - $ / year

** The calculator is based on industry averages and should not be considered an exact estimate.

Request a Quote Now

List of core measure abstraction solutions:

ACHF: Advanced Certification in Heart Failure Measure

  • ACHF-1 Beta-Blocker Therapy (i.e., Bisoprolol, Carvedilol, or Sustained-Release Metoprolol Succinate) for LVSD Prescribed at Discharge
  • ACHF-2 Post-Discharge Appointment for Heart Failure Patients
  • ACHF-3 Care Transition Record Transmitted
  • ACHF-4 Discussion of Advance Directives/Advance Care Planning
  • ACHF-5 Advance Directive Executed
  • ACHF-6 Post-Discharge Evaluation for Heart Failure Patients

AMI: Acute Myocardial Infarction Measures

  • AMI-1 Aspirin at Arrival
  • AMI-2 Aspirin Prescribed at Discharge
  • AMI-3 ACEI or ARB for LVSD
  • AMI-4 Adult Smoking Cessation Advice/Counseling
  • AMI-5 Beta Blocker Prescribed at Discharge
  • AMI-7 Median Time to Fibrinolysis
  • AMI-7a Fibrinolytic Therapy
  • AMI-8 Median Time to Primary PCI
  • AMI-8a Primary PCI Received
  • AMI-10 Statin Prescribed at Discharge

CAC: Children’s Asthma Care Measures

  • CAC-1 Use of Relievers for Inpatient Asthma
  • CAC-2 Use of Systemic Corticosteroids for Inpatient Asthma
  • CAC-3 Home Management Plan of Care Given to Patient/Caregiver

CCM: Care Coordination Measures

  • CCM-1: Reconciled Medication List Received by Patient at Discharge
  • CCM-2: Transition Record with Data Received by Patient at Discharge
  • CCM-3: Timely Transmission of Transition Record

Emergency Department (ED) Throughput

  • ED-1 Median Time—From ED Arrival to ED Departure for Admitted ED Patients
  • ED-2 Median Time—Admit Decision Time to ED Departure for Admitted Patients

HBIPS: Hospital-Based Inpatient Psychiatric Service Measures

  • HBIPS-1 Admission screening for violence risk, substance use, and psychological trauma history
  • HBIPS-2 Hours of physical restraint use
  • HBIPS-3 Hours of seclusion use
  • HBIPS-4 Patients discharged on multiple antipsychotic medications
  • HBIPS-5 Patients discharged on multiple antipsychotic medications with appropriate justification
  • HBIPS-6 Post discharge continuing care plan created
  • HBIPS-7 Post discharge continuing care plan transmitted to next level of care provider upon discharge

HF: Heart Failure Measures

  • HF-1 Discharge Instructions
  • HF-2 Evaluation of LVS Function
  • HF-3 ACEI or ARB for LVSD

HOP: Hospital Outpatient Measures

  • HOP AMI: Acute Myocardial Infarction
    • OP-1 Median Time to Fibrinolysis
    • OP-2 Fibrinolytic Therapy Received
    • OP-3 Median Time to Transfer
    • OP-4 Aspirin at Arrival
    • OP-5 Median Time to ECG
  • HOP CP: Chest Pain Measures
    • OP-4 Aspirin at Arrival
    • OP-5 Median Time to ECG
  • HOP ED Throughput: Emergency Department Throughput
    • OP-18 Median Time From Arrival to Departure
    • OP-20 Door to Diagnostic Evaluation
    • OP-22 ED-Median Time to Pain Management
  • HOP PM: Pain Management
    • OP-21 ED-Median Time to Pain Management for Long Bone Fracture
  • HOP SCIP: Surgical Care Improvement Project
    • OP-6 Timing of Antibiotic Prophylaxis
    • OP-7 Antibiotic Selection
  • HOP STROKE: Stroke
    • OP-23 Head CT or MRI Scan Results for Acute Ischemic Stroke or Hemorrhagic Stroke Patients Who Received Head CT or MRI Scan Interpretation Within 45 Minutes of ED Arrival
  • HOP Web-based Measures
    • OP-29 Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients
    • OP-30 Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use
    • OP-33 External Beam Radiotherapy for Bone Metastases

IMM: Immunization Measures

  • IMM-1 Pneumococcal Immunization (PPV23)
  • IMM-2 Influenza Immunization

Inpatient ED: Emergency Department (ED) Measures

  • ED-1 Median Time from ED Arrival to ED Departure for Admitted ED Patients
  • ED-2 Admit Decision Time to ED Departure Time for Admitted Patients

MassHealth AHQM: Massachusetts Health Acute Hospital Quality Measures

Maternity

  • MAT-3 Elective Delivery < 39-Weeks Gestation
  • MAT-4 Cesarean Birth
  • MAT-5 DVT Prophylaxis for Cesarean Delivery

Newborn

  • NEWB-1 Exclusive Breast Milk Feeding
  • NEWB-2 Newborn Bilirubin Screening

PC: Perinatal Care Measures

  • PC-01 Elective Delivery
  • PC-02 Cesarean Birth
  • PC-03 Antenatal Steroids
  • PC-04 Healthcare-Associated Bloodstream Infections in Newborns
  • PC-05 Exclusive Breast Milk Feeding

PN: Pneumonia Measures

  • PN-3a Blood Cultures Performed Within 24 Hours Prior to or 24 Hours After Hospital Arrival for Patients Who Were Transferred or Admitted to the ICU Within 24 Hours of Hospital Arrival
  • PN-3b Blood Cultures Performed in the Emergency Department Prior to Initial Antibiotic Received
  • PN-6 Initial Antibiotic Selection for Community-Acquired Pneumonia in Immunocompetent

Patients

SCIP: Surgical Care Improvement Project Measures

  • SCIP-Inf-1 Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision
  • SCIP-Inf-2 Prophylactic Antibiotic Selection for Surgical Patients
  • SCIP-Inf-3 Prophylactic Antibiotics Discontinued Within 24 Hours After Surgery End Time
  • SCIP-Inf-4 Cardiac Surgery Patients with Controlled 6 A.M. Postoperative Blood Glucose
  • SCIP-Inf-6 Surgery Patients with Appropriate Hair Removal
  • SCIP-Inf-9 Urinary Catheter Removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with Day of Surgery Being Day Zero
  • SCIP-Inf-10 Surgery Patients with Perioperative Temperature Management
  • SCIP-Card-2 Surgery Patients on Beta-Blocker Therapy Prior to Arrival Who Received a Beta-Blocker During the Perioperative Period
  • SCIP-VTE-1 Surgery Patients with Recommended Venous Thromboembolism Prophylaxis Ordered
  • SCIP-VTE-2 Surgery Patients Who Received Appropriate Venous Thromboembolism Prophylaxis Within 24 Hours Prior to Surgery to 24 Hours After Surgery

SEP: Sepsis Bundle Project Measures

  • SEP-1 Early Management Bundle, Severe Sepsis/Septic Shock

STK: Stroke

  • STK-1 Venous Thromboembolism (VTE) Prophylaxis
  • STK-2 Discharged on Antithrombotic Therapy
  • STK-3 Anticoagulation Therapy for Atrial Fibrillation/Flutter
  • STK-4 Thrombolytic Therapy
  • STK-5 Antithrombotic Therapy By End of Hospital Day 2
  • STK-6 Discharged on Statin Medication
  • STK-8 Stroke Education
  • STK-10 Assessed for Rehabilitation

SUB: Substance Abuse Measures

  • SUB-1 Alcohol Use Screening
  • SUB-2 Alcohol Use Brief Intervention Provided or Offered
  • SUB-2a Alcohol Use Brief Intervention Treatment
  • SUB-3 Alcohol and Other Drug Use Disorder Treatment Provided or Offered at Discharge
  • SUB-3a Alcohol and Other Drug Use Disorder Treatment at Discharge

TOB: Tobacco Treatment Measures

  • TOB-1 Tobacco Use Screening
  • TOB-2 Tobacco Use Treatment Provided or Offered
  • TOB-2a Tobacco Use Treatment
  • TOB-3 Tobacco Use Treatment Provided or Offered at Discharge
  • TOB-3a Tobacco Use Treatment at Discharge

VTE: Venous Thromboembolism Measures

  • VTE-1 Venous Thromboembolism Prophylaxis
  • VTE-2 Intensive Care Venous Thromboembolism Prophylaxis
  • VTE-3 Venous Thromboembolism Patients with Anticoagulation Overlap Therapy
  • VTE-4 Venous Thromboembolism Patients Receiving Unfractionated Heparin With Dosages/Platelet Count Monitoring by Protocol
  • VTE-5 Venous Thromboembolism Discharge Instructions
  • VTE-6 Incidence of Potentially Preventable Venous Thromboembolism

 

Think this list is long?

Look at our registries